플러스100%마이너스

  • 화면크기
통합검색

한의약융합데이터센터


근거중심한의약 DB

Home > 한의약융합데이터센터 > 근거중심한의약 DB
Title

Shugan Jieyu capsule improve sleep and emotional disorder in coronavirus disease 2019 convalescence patients: a randomized, double-blind, placebo-controlled trial.

Authors

Xuedong AN, Qing Z, Junxiu T, Li LI, Yun C, Kejian LI, Jing HE, Ru L, Juan G, Jia Z, Hui Z, Fengmei L, Xiaodong LI.

Journal

J Tradit Chin Med.

Year

2022

Vol (Issue)

42(5)

Page

803-09.

doi

10.19852/j.cnki.jtcm.20220719.003.

PMID

36083489

Url

http://www.ncbi.nlm.nih.gov/pubmed/36083489

MeSH

COVID-19 Drug Treatment*
Convalescence
Double-Blind Method
Humans
Sleep
Treatment Outcome

Keywords

COVID-19; Shugan Jieyu capsule; convalescence; emotional disorder; sleep quality

한글 키워드

코로나19; 서간해울과립; 회복기; 정서 장애; 수면 질

KMCRIC
Summary & Commentary

KMCRIC 비평 보기 +

Korean Study

Abstract

Objective: To evaluate the efficacy of the Shugan Jieyu capsule on improving sleep and emotional disorder during Coronavirus disease 2019 (COVID-19) convalescence.

Methods: We conducted a randomized, double-blind, placebo-controlled trial, and recruit 200 COVID-19 convalescence patients and then divide the subjects into two groups respectively: the experimental group (n=100) and the control group (n=100). Patients in the control group were given doses as a placebo, while those in the experimental group were given Shugan Jieyu capsule. The investigators mainly observed the differences between the two groups before and after treatment in terms of the rate of reduction and the rate of efficiency in Hamilton Depression Scale (HAMD-17) total scores from baseline, and recorded the scores of Hamilton Anxiety Scale (HAMA), Patient Health Questionnaire-15 (PHQ-15), Insomnia Severity Index (ISI) and Treatment Emergent Symptom Scale at 2 week, the 4 week and the 6 week respectively after treatment, and compared the differences between the groups. And the occurrence of adverse events was recorded.

Results: After 6-week treatment, there were statistically significant differences in the rate of reduction as well as efficiency in HAMD-17 scores, HAMA Total Scores, PHQ-15 Score, ISI Score from baseline in the experimental group and control group (< 0.05). There were 4 adverse events in the experimental group and 1 in the control group.

Conclusion: Shugan Jieyu capsule could significantly improve sleep and emotional disorder in patients during COVID-19 convalescence.

국문초록

N

Language

영어

첨부파일